Conclusions Compared with high-dose statin therapy , ezetimibe with low-dose statin for more than 3 months may have a beneficial tendency of effects on glycemic control
Purpose Given the increased risk of incident diabetes and the side effects on glycemic control with statin treatment , statin and ezetimibe combination therapy has been widely used .
However , whether the same concern exists in ezetimibe remains uncertain .
This meta- analysis aim ed to investigate the influence of ezetimibe treatment on glycemic control .
Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
INTRODUCTION Type 2 diabetes is associated with atherogenic abnormalities of postpr and ial triglyceride-rich lipoproteins . This study evaluated whether ezetimibe , by inhibiting intestinal cholesterol absorption , influences chylomicrons and VLDL particles at fasting and after a st and ard meal . METHODS By a double blind cross-over design 15 subjects with type 2 diabetes and hypercholesterolaemia followed in r and om order a 6-week treatment with ezetimibe 10mg+simvastatin 20 mg ( EZE+S ) or placebo+simvastatin 20 mg ( P+S ) and , after a 6-week wash-out period , crossed over to the other treatment ( NCT00699023 ) . At the end of each period lipids , apoB-48 , and apoB-100 concentrations in plasma and lipoprotein fractions ( separated by discontinuous density gradient ultracentrifugation ) were determined before and over 6h following a high-fat test meal . RESULTS Compared with P+S , EZE+S induced , ( a ) beside a greater decrease in LDL cholesterol , ( b ) a significant decrease in chylomicron lipid content both at fasting and postpr and ially ( 4.4 ± 2.7 vs. 8.3 ± 8.7 mg/dl × 6 h total AUC for cholesterol , p < 0.05 ; 18 ± 12 vs. 29 ± 24 mg/dl triglyceride concentrations at 6h , p < 0.05 ) , ( c ) a significant decrease in chylomicron postpr and ial apoB-48 ( 0.03 ± 0.03 vs. 0.09 ± 0.08 mg/l at 4 h , p < 0.05 ) , and ( d ) significant fasting and postpr and ial decreases in the cholesterol content of VLDL , IDL , and LDL , as shown by the significant reduction of the cholesterol/triglyceride ratio in these lipoproteins . CONCLUSIONS A 6-week treatment with ezetimibe and simvastatin , compared to simvastatin alone , positively influences lipoprotein profile both at fasting and postpr and ially in type 2 diabetic patients by favouring the production of cholesterol-poor chylomicrons and VLDL particles that have less atherogenic potential
Conclusions Compared with high-dose statin therapy , ezetimibe with low-dose statin for more than 3 months may have a beneficial tendency of effects on glycemic control
Purpose Given the increased risk of incident diabetes and the side effects on glycemic control with statin treatment , statin and ezetimibe combination therapy has been widely used .
However , whether the same concern exists in ezetimibe remains uncertain .
This meta- analysis aim ed to investigate the influence of ezetimibe treatment on glycemic control .